The Future of Psychiatry [transcript][audio]

Guest: Dr. Gerard Marek

Presenter: Neal Howard

Guest Bio: Gerard Marek earned his MD and PhD (Psychopharmacology) at the University of Chicago in 1989 and 1988.  After completing residency training in Psychiatry at the Yale University in the School of Medicine, he spent another 3 years as a postdoctoral fellow studying single cell electrophysiological recordings in rat brain slices. He then obtained independent RO1 funding after securing a junior faculty position in the Yale Department of Psychiatry in 1997 combining slice Electrophysiology with independent neurochemical and behavioral studies. In January 2002, Gerard joined the Pfizer early clinical development group in Groton working on antidepressants and antipsychotic drugs. He moved to Eli Lilly in October 2003 and spent the majority of 5 years at Lilly leading a Discovery group in Psychiatric Disorders targeting novel antidepressants, antipsychotics, novel treatments for substance abuse and sleep disorders. Gerard then spent 6 years in Neuroscience Clinical Development at AbbVie mostly directed toward developing medications for the symptomatic treatment of Alzheimer’s disease and disease progression of multiple sclerosis with respect to remyelination and neurite sprouting.  He moved to Astellas a little over 3 years ago where he has been leading programs studying cognitive impairment associated with schizophrenia and chronic pain syndromes.

Segment overview: Dr. Gerard Marek discusses the future of neurologic treatments and what is to come from Astellas’ new global hub of innovation in San Diego dubbed ARIA.